Back to results
US 8,394,386 B2Granted
Sequential delivery of immunogenic molecules via adenovirus and adeno-associated virus-mediated administrations
AssigneeThe Trustees of the University of Pennsylvania
InventorJames M. Wilson
Life of this patent
Estimating the term…
Abstract
An immunogenic regimen is provided. The regimen involves sequential administration of a recombinant adenoviral vector and a recombinant adeno-associated viral vector, each of which delivers a heterologous expression cassette encoding the same immunogenic product, or a cross-reactive immunogenic product. Also provided are products containing the vectors for use in the regimen of the invention.
Claims23
An immunization regimen comprising delivering to a subject:
- (a) a replication-defective adenovirus comprising a first heterologous expression cassette comprising a nucleic acid sequence encoding a product for inducing an immune response to said product under the control of regulatory control sequences which direct expression of said product;
- and
- (b) an adeno-associated virus (AAV) comprising a second heterologous expression cassette comprising a nucleic acid sequence encoding said product for inducing an immune response to said product under the control of regulatory control sequences which direct expression of said product,
- wherein the AAV is delivered prior to delivery of the replication-defective adenovirus.
1 more element
A method of inducing an antigen-specific humoral or T-cell response in a subject, comprising administering:
- (a) a replication-defective adenovirus vector comprising a first heterologous expression cassette comprising a nucleic acid sequence encoding a product for inducing an antigen-specific humoral or T-cell response to said product under the control of regulatory control sequences which direct expression of said product;
- and
- (b) an adeno-associated virus (AAV) vector comprising a second heterologous expression cassette comprising nucleic acid sequence encoding said product for inducing an antigen-specific humoral or T-cell response to said product under the control of regulatory control sequences which direct expression of said product
- wherein said replication-defective adenovirus vector is administered after said adeno-associated virus (AAV) vector.
1 more element
Dependencies are inferred from the claim text.